ADMA Biologics Under Investigation for Securities Fraud Allegations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 03 2026
0mins
Source: Globenewswire
- Investigation Announcement: Bleichmar Fonti & Auld LLP has initiated an investigation into ADMA Biologics for potential violations of federal securities laws, urging investors to seek additional information regarding their legal options.
- Revenue Growth Scrutiny: While ADMA Biologics reported a 20% revenue growth in 2025, allegations suggest this was achieved through a channel stuffing scheme to obscure declining demand, with actual revenues potentially declining by 3% without such practices.
- Stock Price Plunge: Following the release of a report by Culper Research that exposed these channel stuffing allegations, ADMA Biologics' stock price fell by 29% over two trading days, from $13.59 to $9.63 per share, indicating significant market concerns about the company's financial integrity.
- Legal Implications: Investors may have legal recourse, as BFA offers representation on a contingency fee basis, emphasizing their commitment to protecting investor rights, which could also impact ADMA's future financing capabilities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADMA
About ADMA
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
B Group Increases Stake in ADMA Biologics by 750,000 Shares
- Share Increase: B Group disclosed a purchase of 750,000 shares of ADMA Biologics in a May 15, 2026 SEC filing, with an estimated transaction value of $11.84 million, indicating continued confidence in the company.
- Holding Proportion: Following this acquisition, B Group's stake in ADMA reached 3,207,542 shares valued at $28.90 million, representing 21.43% of its assets under management, highlighting the stock's significance in its portfolio.
- Financial Performance: Despite ADMA's stock price plummeting 58% over the past year, the first quarter saw a 22% increase in adjusted net income to $40.7 million, demonstrating the company's resilience and potential for future growth.
- Market Outlook: Revenue from ADMA's ASCENIV product surged 28% year-over-year to $97.5 million, with management expressing optimism about future growth, and B Group's stake increase reflects confidence in ADMA's long-term investment value.
See More
ADMA Biologics Under Investigation for Securities Fraud Allegations
- Investigation Background: Bleichmar Fonti & Auld LLP has announced an investigation into ADMA Biologics for potential violations of federal securities laws, focusing on allegations that its reported 20% revenue growth in 2025 was a result of a channel stuffing scheme to mask declining demand.
- Revenue Growth Scrutiny: A report by Culper Research revealed that ADMA allegedly induced a distributor to stockpile ASCENIV by offering rebates and extended payment terms, which allowed the company to report a 20% growth that was not genuine; without this scheme, revenue would have declined by 3% in 2025.
- Stock Price Impact: This news caused ADMA Biologics' stock price to plummet by $3.96, or 29%, over two trading days, dropping from $13.59 per share on March 23, 2026, to $9.63 per share on March 25, indicating significant market concerns regarding its financial health.
- Legal Options for Investors: Investors are encouraged to submit their information to BFA to explore legal options, with the firm offering representation on a contingency fee basis, highlighting its commitment to protecting investor rights.
See More
B Group Increases Stake in ADMA Biologics
- Share Acquisition: B Group purchased 750,000 shares of ADMA Biologics in Q1, with an estimated transaction value of $11.84 million, reflecting a long-term confidence in the company.
- Position Change: By quarter-end, B Group's total stake in ADMA reached 3,207,542 shares valued at $28.90 million, despite a net position decline of $15.93 million due to stock price fluctuations.
- Market Dynamics: ADMA Biologics reported flat Q1 revenue of $114.5 million, yet adjusted net income rose 22% to $40.7 million, demonstrating resilience in the immunology and infectious disease markets.
- Strategic Implications: Despite pricing pressures, B Group sees potential in ADMA's ASCENIV product, which grew 28% year-over-year to $97.5 million, indicating future growth opportunities and strengthening its competitive position in the biopharmaceutical sector.
See More
B Group Acquires Stake in Bright Minds Biosciences
- New Investment Position: B Group disclosed in its May 15, 2026 SEC filing that it acquired 67,500 shares of Bright Minds Biosciences for an estimated $5.43 million, indicating confidence in the company's future growth potential.
- Significant Stake: This acquisition represents approximately 4% of B Group's reportable AUM, reflecting its strategic positioning within the biotechnology sector.
- Strong Market Performance: Bright Minds' shares have surged nearly 175% over the past year, significantly outperforming the S&P 500's 25% increase, highlighting market confidence in its drug development prospects.
- Increased R&D Investment: Bright Minds ramped up its R&D spending to C$18.7 million in the first half of fiscal 2026, a substantial increase from C$3.6 million a year earlier, demonstrating accelerated efforts in developing its lead drug BMB-101 for drug-resistant epilepsy.
See More
ADMA Biologics Under Investigation for Securities Fraud
- Investigation Background: Bleichmar Fonti & Auld LLP has announced an investigation into ADMA Biologics for potential securities fraud, as the reported 20% revenue growth in 2025 may have been achieved through channel stuffing, indicating serious issues with the company's financial transparency.
- Revenue Manipulation Allegations: A report by Culper Research claims that ADMA induced a distributor to stockpile ASCENIV by offering rebates and extended payment terms, suggesting that the company would have faced a 3% revenue decline instead of the reported 20% growth, reflecting misconduct in market operations.
- Stock Price Plunge: The news of the investigation caused ADMA Biologics' stock to drop 29% over two trading days, from $13.59 per share on March 23 to $9.63 per share on March 25, highlighting investor concerns regarding the company's financial health.
- Legal Options for Investors: Investors are encouraged to submit their information for legal assistance, with BFA offering representation on a contingency fee basis, emphasizing the firm's commitment to protecting shareholder rights.
See More
Rosen Law Firm Investigates ADMA Biologics for Potential Securities Claims
- Securities Investigation: Rosen Law Firm is investigating potential securities claims against ADMA Biologics for allegedly issuing misleading business information, indicating significant legal risks that could undermine shareholder confidence and stock performance.
- Stock Price Plunge: On March 24, 2026, ADMA Biologics shares fell 16.6% after short seller Culper Research accused the company of channel stuffing to inflate revenue, reflecting market concerns over the company's financial transparency.
- Class Action Preparation: The Rosen Law Firm is preparing a class action lawsuit against ADMA Biologics, allowing investors to seek compensation without any out-of-pocket costs, which could result in substantial financial liabilities for the company.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating a strong track record that may encourage more affected investors to join the lawsuit.
See More
B Group Increases Stake in ADMA Biologics by 750,000 Shares
- Share Increase: B Group disclosed a purchase of 750,000 shares of ADMA Biologics in a May 15, 2026 SEC filing, with an estimated transaction value of $11.84 million, indicating continued confidence in the company.
- Holding Proportion: Following this acquisition, B Group's stake in ADMA reached 3,207,542 shares valued at $28.90 million, representing 21.43% of its assets under management, highlighting the stock's significance in its portfolio.
- Financial Performance: Despite ADMA's stock price plummeting 58% over the past year, the first quarter saw a 22% increase in adjusted net income to $40.7 million, demonstrating the company's resilience and potential for future growth.
- Market Outlook: Revenue from ADMA's ASCENIV product surged 28% year-over-year to $97.5 million, with management expressing optimism about future growth, and B Group's stake increase reflects confidence in ADMA's long-term investment value.
See More
ADMA Biologics Under Investigation for Securities Fraud Allegations
- Investigation Background: Bleichmar Fonti & Auld LLP has announced an investigation into ADMA Biologics for potential violations of federal securities laws, focusing on allegations that its reported 20% revenue growth in 2025 was a result of a channel stuffing scheme to mask declining demand.
- Revenue Growth Scrutiny: A report by Culper Research revealed that ADMA allegedly induced a distributor to stockpile ASCENIV by offering rebates and extended payment terms, which allowed the company to report a 20% growth that was not genuine; without this scheme, revenue would have declined by 3% in 2025.
- Stock Price Impact: This news caused ADMA Biologics' stock price to plummet by $3.96, or 29%, over two trading days, dropping from $13.59 per share on March 23, 2026, to $9.63 per share on March 25, indicating significant market concerns regarding its financial health.
- Legal Options for Investors: Investors are encouraged to submit their information to BFA to explore legal options, with the firm offering representation on a contingency fee basis, highlighting its commitment to protecting investor rights.
See More
B Group Increases Stake in ADMA Biologics
- Share Acquisition: B Group purchased 750,000 shares of ADMA Biologics in Q1, with an estimated transaction value of $11.84 million, reflecting a long-term confidence in the company.
- Position Change: By quarter-end, B Group's total stake in ADMA reached 3,207,542 shares valued at $28.90 million, despite a net position decline of $15.93 million due to stock price fluctuations.
- Market Dynamics: ADMA Biologics reported flat Q1 revenue of $114.5 million, yet adjusted net income rose 22% to $40.7 million, demonstrating resilience in the immunology and infectious disease markets.
- Strategic Implications: Despite pricing pressures, B Group sees potential in ADMA's ASCENIV product, which grew 28% year-over-year to $97.5 million, indicating future growth opportunities and strengthening its competitive position in the biopharmaceutical sector.
See More
B Group Acquires Stake in Bright Minds Biosciences
- New Investment Position: B Group disclosed in its May 15, 2026 SEC filing that it acquired 67,500 shares of Bright Minds Biosciences for an estimated $5.43 million, indicating confidence in the company's future growth potential.
- Significant Stake: This acquisition represents approximately 4% of B Group's reportable AUM, reflecting its strategic positioning within the biotechnology sector.
- Strong Market Performance: Bright Minds' shares have surged nearly 175% over the past year, significantly outperforming the S&P 500's 25% increase, highlighting market confidence in its drug development prospects.
- Increased R&D Investment: Bright Minds ramped up its R&D spending to C$18.7 million in the first half of fiscal 2026, a substantial increase from C$3.6 million a year earlier, demonstrating accelerated efforts in developing its lead drug BMB-101 for drug-resistant epilepsy.
See More
ADMA Biologics Under Investigation for Securities Fraud
- Investigation Background: Bleichmar Fonti & Auld LLP has announced an investigation into ADMA Biologics for potential securities fraud, as the reported 20% revenue growth in 2025 may have been achieved through channel stuffing, indicating serious issues with the company's financial transparency.
- Revenue Manipulation Allegations: A report by Culper Research claims that ADMA induced a distributor to stockpile ASCENIV by offering rebates and extended payment terms, suggesting that the company would have faced a 3% revenue decline instead of the reported 20% growth, reflecting misconduct in market operations.
- Stock Price Plunge: The news of the investigation caused ADMA Biologics' stock to drop 29% over two trading days, from $13.59 per share on March 23 to $9.63 per share on March 25, highlighting investor concerns regarding the company's financial health.
- Legal Options for Investors: Investors are encouraged to submit their information for legal assistance, with BFA offering representation on a contingency fee basis, emphasizing the firm's commitment to protecting shareholder rights.
See More
Rosen Law Firm Investigates ADMA Biologics for Potential Securities Claims
- Securities Investigation: Rosen Law Firm is investigating potential securities claims against ADMA Biologics for allegedly issuing misleading business information, indicating significant legal risks that could undermine shareholder confidence and stock performance.
- Stock Price Plunge: On March 24, 2026, ADMA Biologics shares fell 16.6% after short seller Culper Research accused the company of channel stuffing to inflate revenue, reflecting market concerns over the company's financial transparency.
- Class Action Preparation: The Rosen Law Firm is preparing a class action lawsuit against ADMA Biologics, allowing investors to seek compensation without any out-of-pocket costs, which could result in substantial financial liabilities for the company.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating a strong track record that may encourage more affected investors to join the lawsuit.
See More
